熱門資訊> 正文
Janux Therapeutics在Deciphera收购交易后上涨28%
2024-04-30 03:49
- Janux Therapeutics (NASDAQ:JANX) rose as much as 28% in Monday trading following the announcement earlier in the day that fellow oncology-focused drug developer Deciphera Pharmaceuticals (DCPH) was being acquired by Japan’s ONO Pharmaceutical for $2.4B.
- Janux has been no stranger to M&A chatter of late. Earlier this month, it was reported the biopharma was weighing options after several large pharmas expressed takeover interest.
- Trading volume is slightly higher than usual for the stock. As of 345p ET, ~1.3M shares had changed hands. The average is ~1.1M.
- As of 345p ET, Janux (JANX) was up ~20%.
More on Janux Therapeutics
- Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
- Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here
- Trial Data Triggers Massive Rally In Janux Therapeutics
- Janux a new buy at Jones on lead assets for solid tumors
- Janux Therapeutics surges amid report of takeover interest
推薦文章
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
一周IPO | 賺錢效應持續火熱！年內24只上市新股「0」破發；「圖模融合第一股」海致科技首日飆漲逾242%
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
美股機會日報 | 降息預期升溫！美國1月CPI年率創去年5月來新低；淨利、指引雙超預期！應用材料盤前漲超10%
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
